XML 20 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Statements of Operations-Additional Information
6 Months Ended
Dec. 31, 2018
Statements Of Operations Additional Information [Abstract]  
Statements of Operations-Additional Information
3.      Statements of Operations—Additional Information
 
Disaggregated revenue, deferred revenue and customer payment terms
We develop, manufacture and market products for a broad range of food animals including poultry, swine, beef and dairy cattle and aquaculture. The products help prevent, control and treat diseases, enhance nutrition to help improve health and contribute to balanced mineral nutrition. The animal health and mineral nutrition products are sold either directly to integrated poultry, swine and cattle integrators or through commercial animal feed manufacturers, wholesalers and distributors. The animal health industry and demand for many of the animal health products in a particular region are affected by changing disease pressures and by weather conditions, as product usage follows varying weather patterns and seasons. Our operations are primarily focused in regions where the majority of livestock production is consolidated in large commercial farms.
We have a diversified portfolio of products that are classified within our three business segments—Animal Health, Mineral Nutrition and Performance Products. Each segment has its own dedicated management and sales team.
Animal Health
The Animal Health business develops, manufactures and markets products in three main categories:
•      MFAs and Other:   The MFAs and other business primarily consists of concentrated medicated products that are administered through animal feeds, commonly referred to as Medicated Feed Additives (“MFAs”). Specific product classifications include antibacterials, which inhibit the growth of pathogenic bacteria that cause bacterial infections in animals; anticoccidials, which inhibit the growth of coccidia (parasites) that damage the intestinal tract of animals; and other related products.
 
•      Nutritional Specialties:   Nutritional specialty products enhance nutrition to help improve health and performance in areas such as immune system function and digestive health.
 
•      Vaccines:   Our vaccines are primarily focused on preventing diseases in poultry and swine. They protect animals from either viral or bacterial disease challenges. We also manufacture and distribute autogenous vaccine products and market adjuvants to vaccine manufacturers. We have developed an innovative and proprietary delivery platform for vaccines.
 
Mineral Nutrition
The Mineral Nutrition business is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. The customers use these products to fortify the daily feed requirements of their livestock’s diets and maintain an optimal balance of trace elements in each animal. Mineral nutrition products are manufactured and marketed for a broad range of food animals including poultry, swine and beef and dairy cattle.
Performance Products
The Performance Products business manufactures and markets a number of specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries, predominantly in the United States.
The following tables present our revenues disaggregated by major product category and geographic region:
Net Sales by Product Type
     
Three Months
   
Six Months
 
For the Periods Ended December 31
   
2018
   
2017
   
2018
   
2017
 
Animal Health                                                  
MFAs and other
      $ 93,054         $ 82,018         $ 180,058         $ 161,621    
Nutritional specialties
        29,460           32,623           56,430           63,400    
Vaccines
        17,048           18,204           34,263           36,665    
Total Animal Health
      $ 139,562         $ 132,845         $ 270,751         $ 261,686    
Mineral Nutrition
        62,319           59,616           117,157           111,689    
Performance Products
        16,342           13,415           30,468           25,913    
Total
      $ 218,223         $ 205,876         $ 418,376         $ 399,288    
 
Net Sales by Region
     
Three Months
   
Six Months
 
For the Periods Ended December 31
   
2018
   
2017
   
2018
   
2017
 
United States
      $ 127,750         $ 129,379         $ 243,842         $ 242,548    
Latin America and Canada
        39,316           36,126           77,575           68,452    
Europe, Middle East and Africa
        26,181           27,672           51,040           53,054    
Asia Pacific
        24,976           12,699           45,919           35,234    
Total
      $ 218,223         $ 205,876         $ 418,376         $ 399,288    
 
Net sales by region are based on country of destination.
Total deferred revenue was $6,416 and $4,530 as of December 31, 2018 and June 30, 2018, respectively. Accrued expenses and other current liabilities included $1,471 and $508 of the total deferred revenue as of December 31, 2018 and June 30, 2018, respectively. The deferred revenue resulted primarily from certain customer arrangements, including technology licensing fees and discounts on future product sales. The transaction price associated with our deferred revenue arrangements is generally based on the stand alone sales prices of the individual products or services.
Our customer payment terms generally range from 30 to 120 days globally and do not include any significant financing components. Payment terms vary based on industry and business practices within the regions in which we operate. Our average worldwide collection period for accounts receivable is approximately 60 days after the revenue is recognized.
Interest expense and Depreciation and amortization
     
Three Months
   
Six Months
 
For the Periods Ended December 31
   
2018
   
2017
   
2018
   
2017
 
Interest expense, net                                                  
Term loan
      $ 2,202         $ 2,110         $ 4,314         $ 4,143    
Revolving credit facility
        920           739           1,667           1,420    
Amortization of debt issuance costs and debt discount
        220           220           441           441    
Acquisition-related accrued interest
                  252                     505    
Other
        120           2           283           241    
Interest expense
        3,462           3,323           6,705           6,750    
Interest (income)
        (447)           (273)           (907)           (582)    
        $ 3,015         $ 3,050         $ 5,798         $ 6,168    
Depreciation and amortization                                                  
Depreciation of property, plant and equipment
      $ 5,308         $ 5,222         $ 10,496         $ 10,405    
Amortization of intangible assets
        1,521           1,397           3,012           2,846    
Amortization of other assets
        12           12           24           24    
        $ 6,841         $ 6,631         $ 13,532         $ 13,275